Depomed (NASDAQ:DEPO), a specialty pharmaceutical company, reported positive updates in it’s most recent 10Q regarding it’s phase 1 clinical trial for the treatment of Parkinson’s disease with DM-1992, a novel sustained-release formulation of LevoDopa/Carbidopa. According to the company’s 10Q, Depomed completed the study in early August of 2009. “In the study, DM-1992 extended coverage above […]
Merck beefing up diabetes pipeline
Merck acquires non-exclusive license for Acuform technology from Depomed Merck plans to use technology to expand it’s diabetes portfolio Signifies the extended release diabetes market is growing more competitive Pharmaceutical pipeline weaknesses will spur more deals. Today, Merck (NYSE:MRK) signaled that it will be expanding it’s diabetes pipeline. Merck announced that it has licensed certain […]
Women’s Health: Who can handle the heat for Hot Flashes?
After the Women’s Health Initiative there is an opportunity for new non-hormonal treatments for menopausal symptoms Some estimates believe this market may be up to $8 Billion USD Before the Women’s Health Initiative (‘WHI’), women were effectively treating their menopausal symptoms with hormone replacement therapy (‘HRT’), such as Premarin, Prempro and others. But since then, […]
DepoMed: Protected by Cash and Headed Higher
Recently, my partner has made some great stock picks for his portfolio. The markets now are truly once in a lifetime and these sort of gyrations can present huge opportunities to us small time investors. His portfolio is up 75% month-over-month. I got to give him props. But let me make a case for Depomed (NASDAQ:DEPO). […]
